Welcome Center  |   Log In  |   Register  |   Follow Us  Facebook  Twitter Google Plus

The Incretin Pathway: A new area of treatment for Type 2 diabetes.

Compounds that effect GLP-1, GIP and DPP-4.

Zachary Bloomgarden, MD, Editor of The Journal of Diabetes and Clinical Professor in the Dept. of Medicine at the Mount Sinai School of Medicine, discusses the use of drugs that affect the incretin pathway in treating diabetes.

Speaker’s Bureau: Merck, NovoNordisk, GSK
Advisory Panel: Merck, BMS, Astra Zeneca, Boehringer Ingelheim, Biodel
Consultant: Merck, Novartis, Dainippon Sumitomo Pharma America, Forest Laboratories
Stock/Shareholder: Covidien, Bard, Novartis, Roche, Stryker